Alceus Bio is developing multimodal CAR T-cell therapies engineered to overcome the immunosuppressive tumor microenvironment and enhance T-cell persistence in solid cancers. Their proprietary synthetic biology platforms aim to reprogram the tumor microenvironment and extend the functional longevity of T-cells, leading to more durable therapeutic outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current CAR T-cell therapies exhibit limited efficacy against solid tumors due to insufficient T-cell persistence and the immunosuppressive nature of the tumor microenvironment. These limitations result in suboptimal and transient patient responses.
Solution
Alceus Bio is developing a novel class of multimodal CAR T-cell therapies engineered to address the inherent challenges of solid cancers. The company leverages proprietary synthetic biology platforms to enhance T-cell persistence and actively reprogram the tumor microenvironment. This approach aims to overcome resistance mechanisms, extend functional longevity of T-cells, and ultimately deliver more durable and effective therapeutic outcomes for patients with solid tumors.
Target Audience
The primary target audience includes oncologists, clinical researchers, and pharmaceutical companies focused on developing advanced cell therapies for solid tumor indications.
Features
- Synthetic biology platforms designed to enhance CAR T-cell persistence and functional longevity.
- Reprogramming of the tumor microenvironment to counteract immunosuppressive factors.
- Engineering of T-cells to overcome resistance mechanisms prevalent in solid tumors.
- Development of multimodal therapeutic strategies for solid cancer indications.